Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Thymic malignancies: from clinical management to targeted therapies.

Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G.

J Clin Oncol. 2011 Dec 20;29(36):4820-7. doi: 10.1200/JCO.2011.36.0487. Epub 2011 Nov 21. Review.

2.

Thymic tumors: relevant molecular data in the clinic.

Girard N.

J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S291-5. doi: 10.1097/JTO.0b013e3181f209b9. Review.

3.

Targeted therapies for thymic malignancies.

Girard N.

Thorac Surg Clin. 2011 Feb;21(1):115-23, viii. doi: 10.1016/j.thorsurg.2010.08.004. Review.

PMID:
21070993
5.

Chemotherapy and targeted agents for thymic malignancies.

Girard N.

Expert Rev Anticancer Ther. 2012 May;12(5):685-95. doi: 10.1586/era.12.29. Review.

PMID:
22594902
6.

Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.

Simonelli M, Zucali PA, Suter MB, Lorenzi E, Rubino L, Fatuzzo G, Alloisio M, Santoro A.

Future Oncol. 2015;11(8):1223-32. doi: 10.2217/fon.14.318. Review.

PMID:
25832879
7.

Systemic treatment of advanced thymic malignancies.

Kelly RJ.

Am Soc Clin Oncol Educ Book. 2014:e367-73. doi: 10.14694/EdBook_AM.2014.34.e367. Review.

8.

Do thymic malignancies respond to target therapies?

Hu B, Rong H, Han Y, Li Q.

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):855-9. doi: 10.1093/icvts/ivv040. Epub 2015 Mar 8. Review.

9.

Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer.

Forde PM, Kelly RJ.

J Thorac Oncol. 2013 Jun;8(6):673-84. doi: 10.1097/JTO.0b013e31828b5172.

10.

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.

Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W.

Clin Cancer Res. 2009 Nov 15;15(22):6790-9. doi: 10.1158/1078-0432.CCR-09-0644. Epub 2009 Oct 27.

11.

Treatment updates in advanced thymoma and thymic carcinoma.

Gubens MA.

Curr Treat Options Oncol. 2012 Dec;13(4):527-34. doi: 10.1007/s11864-012-0211-7.

PMID:
22961051
12.

Mutational status of EGFR and KIT in thymoma and thymic carcinoma.

Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K, Saijo N.

Lung Cancer. 2008 Dec;62(3):316-20. doi: 10.1016/j.lungcan.2008.03.013. Epub 2008 Apr 29.

PMID:
18448188
13.

Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review.

Berardi R, De Lisa M, Pagliaretta S, Onofri A, Morgese F, Savini A, Ballatore Z, Caramanti M, Santoni M, Mazzanti P, Cascinu S.

Cancer Treat Rev. 2014 May;40(4):495-506. doi: 10.1016/j.ctrv.2013.11.003. Epub 2013 Nov 26. Review.

PMID:
24355362
14.

[Chemotherapy for thymic carcinoma].

Okuma Y.

Gan To Kagaku Ryoho. 2012 May;39(5):702-7. Japanese.

PMID:
22584319
15.

Targeted therapy for advanced thymic tumors.

Rajan A, Giaccone G.

J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S361-4. doi: 10.1097/JTO.0b013e3181f21114. Review.

16.

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.

Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni G, Boni C.

Anticancer Res. 2014 Sep;34(9):5105-10.

PMID:
25202099
17.

Thymoma versus thymic carcinoma: differences in biology impacting treatment.

Kelly RJ.

J Natl Compr Canc Netw. 2013 May 1;11(5):577-83. Review.

PMID:
23667207
18.

Treatment of advanced thymoma and thymic carcinoma.

Rajan A, Giaccone G.

Curr Treat Options Oncol. 2008 Dec;9(4-6):277-87. doi: 10.1007/s11864-009-0083-7. Epub 2009 Apr 21. Review.

PMID:
19381821
19.

[Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France].

Hadoux J, Girard N, Besse B.

Bull Cancer. 2012 Nov;99(11):1045-55. doi: 10.1684/bdc.2012.1659. Review. French.

PMID:
23131309
20.

Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.

Loehrer PJ Sr, Wang W, Johnson DH, Aisner SC, Ettinger DS; Eastern Cooperative Oncology Group Phase II Trial.

J Clin Oncol. 2004 Jan 15;22(2):293-9. Erratum in: J Clin Oncol. 2004 Jun 1;22(11):2261.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk